Drug Profile
Somatrogon - OPKO Health/Pfizer
Alternative Names: hGH-CTP; Human growth hormone-CTP; Lagova™; Long-acting CTP-enhanced human growth hormone; MOD-4023; NGENLA; PF-06836922Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Modigene
- Developer OPKO Health; Pfizer
- Class Biological proteins; Growth hormones; Hormonal replacements; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Somatotropin deficiency
Most Recent Events
- 30 Nov 2023 OPKO Health completes a phase II trial for Somatotropin deficiency (In children) in USA, Belarus, Greece, Hungary, Russia and Ukraine (NCT02500316)
- 28 Jun 2023 Registered for Somatotropin deficiency (In children) in USA (SC)
- 28 Jun 2023 Pfizer plans to launch Somatrogon (NGENLA) in US by August 2023.